T1	intervention 79 101	lipegfilgrastim (XM22)
T2	No-of-participants 439 442	208
T3	eligibility 443 470	chemotherapy-naive patients
T4	eligibility 105 162	breast cancer patients receiving myelosuppressive therapy
T5	outcome-Measure 749 796	duration of severe neutropenia (DSN) in cycle 1
T6	outcome 848 888	shorter DSN in cycle 1 with higher doses
T7	outcome 894 902	mean DSN
T8	outcome 1133 1254	higher absolute neutrophil count (ANC) at nadir, shorter ANC recovery time, and a similar safety and tolerability profile
